TY - GEN A1 - Dinter, Franziska A1 - Jurischka, Christoph A1 - Weiss, Romano A1 - Rödiger, Stefan T1 - Multiparametrische Antikörperdetektion für die Diagnostik T2 - BIOspektrum Y1 - 2020 U6 - https://doi.org/10.1077/s12268-020-1375-5 SN - 1868-6249 SN - 0947-0867 VL - 26 IS - 3 SP - 265 EP - 267 ER - TY - GEN A1 - Dinter, Franziska A1 - Burdukiewicz, Michał A1 - Schierack, Peter A1 - Lehmann, Werner A1 - Nestler, Jörg A1 - Dame, Gregory A1 - Rödiger, Stefan T1 - Simultaneous detection and quantification of DNA and protein biomarkers in spectrum of cardiovascular diseases in a microfluidic microbead chip T2 - Analytical and Bioanalytical Chemistry Y1 - 2019 U6 - https://doi.org/10.1007/s00216-019-02199-x SN - 1618-2650 SN - 1618-2642 VL - 411 IS - 29 SP - 7725 EP - 7735 ER - TY - GEN A1 - Jurischka, Christoph A1 - Dinter, Franziska A1 - Efimova, Anastasia A1 - Weiss, Romano A1 - Schiebel, Juliane A1 - Schulz, Christian A1 - Fayziev, Bekzodjon A1 - Schierack, Peter A1 - Fischer, Thomas A1 - Rödiger, Stefan T1 - An explorative study of polymers for 3D printing of bioanalytical test systems T2 - Clinical Hemorheology and Microcirculation N2 - Background: The 3D printing is relevant as a manufacturing technology of functional models for forensic, pharmaceutical and bioanalytical applications such as drug delivery systems, sample preparation and point-of-care tests. Objective: Melting behavior and autofluorescence of materials are decisive for optimal printing and applicability of the product which are influenced by varying unknown additives. Methods: We have produced devices for bioanalytical applications from commercially available thermoplastic polymers using a melt-layer process. We characterized them by differential scanning calorimetry, fluorescence spectroscopy and functional assays (DNA capture assay, model for cell adhesion, bacterial adhesion and biofilm formation test). Results: From 14 tested colored, transparent and black materials we found only deep black acrylonitrile-butadiene-styrene (ABS) and some black polylactic acid (PLA) useable for fluorescence-based assays, with low autofluorescence only in the short-wave range of 300-400 nm. PLA was suitable for standard bioanalytical purposes due to a glass transition temperature of approximately 60°C, resistance to common laboratory chemicals and easy print processing. For temperature-critical methods, such as hybridization reactions up to 90°C, ABS was better suited. Conclusions: Autofluorescence was not a disadvantage per se but can also be used as a reference signal in assays. The rapid development of individual protocols for sample processing and analysis required the availability of a material with consistent quality over time. For fluorescence-based assays, the use of commercial standard materials did not seem to meet this requirement. KW - Thermal analysis KW - 3D Printing Y1 - 2020 UR - https://pubmed.ncbi.nlm.nih.gov/31929149/ U6 - https://doi.org/10.3233/CH-190713 SN - 1875-8622 VL - 75 IS - 1 SP - 57 EP - 84 ER - TY - GEN A1 - Deutschmann, Claudia A1 - Dinter, Franziska A1 - Rödiger, Stefan A1 - Roggenbuck, Dirk A1 - Schierack, Peter T1 - Comparison of Lab and Point of Care (POC) technologies – case study for CHI3L1, Potsdam Days on Bioanalysis Y1 - 2017 UR - https://www.researchgate.net/publication/321419307 ER - TY - GEN A1 - Dinter, Franziska A1 - Deutschmann, Claudia A1 - Schierack, Peter A1 - Dame, Gregory A1 - Rödiger, Stefan T1 - Integration of Cardiovascular Disease Biomarkers in a Microfluidic Microbead Chip Y1 - 2017 UR - https://f1000research.com/posters/6-2136 N1 - Potsdam Days on Bioanalysis 2017 ER - TY - GEN A1 - Azam, Hafiz Muhammad Husnain A1 - Rößling, Rosa Ilse A1 - Geithe, Christiane A1 - Khan, Muhammad Moman A1 - Dinter, Franziska A1 - Hanack, Katja A1 - Prüß, Harald A1 - Husse, Britta A1 - Roggenbuck, Dirk A1 - Schierack, Peter A1 - Rödiger, Stefan T1 - MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review T2 - Frontiers in Molecular Neuroscience N2 - Neurodegenerative diseases (NDs) are characterized by abnormalities within neurons of the brain or spinal cord that gradually lose function, eventually leading to cell death. Upon examination of affected tissue, pathological changes reveal a loss of synapses, misfolded proteins, and activation of immune cells—all indicative of disease progression—before severe clinical symptoms become apparent. Early detection of NDs is crucial for potentially administering targeted medications that may delay disease advancement. Given their complex pathophysiological features and diverse clinical symptoms, there is a pressing need for sensitive and effective diagnostic methods for NDs. Biomarkers such as microRNAs (miRNAs) have been identified as potential tools for detecting these diseases. We explore the pivotal role of miRNAs in the context of NDs, focusing on Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Huntington’s disease, and Amyotrophic Lateral Sclerosis. The review delves into the intricate relationship between aging and NDs, highlighting structural and functional alterations in the aging brain and their implications for disease development. It elucidates how miRNAs and RNA-binding proteins are implicated in the pathogenesis of NDs and underscores the importance of investigating their expression and function in aging. Significantly, miRNAs exert substantial influence on post-translational modifications (PTMs), impacting not just the nervous system but a wide array of tissues and cell types as well. Specific miRNAs have been found to target proteins involved in ubiquitination or de-ubiquitination processes, which play a significant role in regulating protein function and stability. We discuss the link between miRNA, PTM, and NDs. Additionally, the review discusses the significance of miRNAs as biomarkers for early disease detection, offering insights into diagnostic strategies. KW - neurodegenerative diseases KW - microRNA KW - biomarkers KW - nervous system KW - diagnostic tools KW - therapeutic tools KW - protein post-translational modifications KW - limitations Y1 - 2024 U6 - https://doi.org/10.3389/fnmol.2024.1386735 SN - 1662-5099 VL - 17 PB - Frontiers Media S.A. ER -